---
document_datetime: 2023-09-21 17:26:11
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/quintanrix-epar-procedural-steps-taken-authorisation_en.pdf
document_name: quintanrix-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3991589
conversion_datetime: 2025-12-21 18:01:40.416291
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

Medicinal Product no longer authorised The applicant GlaxoSmithKline  submitted on  22 May 2003 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for Quintanrix, in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: P.Neels Co-Rapporteur: P.Rossi Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 23 June 2003. · The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 12 September 2003. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 12 September 2003. · During  the  meeting  on  21-22  October  2003  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  23 October 2003. · The applicant submitted the responses to the CHMP consolidated List of Questions on 15 April 2004. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 18 May 2004. · During the CHMP meeting on 23 June 2004, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant. · The applicant submitted the responses to the CHMP list of outstanding issues on 3 September 2004. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of outstanding issues to all CHMP members on  24 September 2004. · During  the  meeting  on    19-21  October  2004,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Quintanrix on 21 October 2004. The applicant provided the letter of undertaking dated 19 October 2004 on the follow-up measures to be fulfilled postauthorisation. · The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 17 February 2005.